Dr. Eugenia Negredo has attended the XIV Meeting on Metabolic Disorders and Comorbidities in HIV infection organized by GEAM (Study Group on AIDS metabolic disorders). It has been celebrated in Marbella from 29 to 31 May.
Some of the drugs used to combat HIV have been associated with increased cardiovascular risk. These drugs, particularly those belonging to the family of protease inhibitors, can cause, for example, an increase in cholesterol and triglycerides. But more recently is believed to also have a negative effect on the endothelium (the inner lining of all blood vessels). The Fight AIDS Foundation is conducting a study to assess the effects of the three most commonly used protease inhibitors (atazanavir, lopinavir and darunavir) and rilpivirine (a new non-nucleoside) in the properties and functions of the endothelium to assess the cardiovascular risk.
In the "IP-endothelium" study, specifically, participants are divided into three groups to collect data from people with HIV who have just started treatment with protease inhibitors (group 1), non-nucleoside transcriptase inhibitors (group 2) and HIV negative (group 3). Then the state of the endothelium can be compared, depending on whether or not received antiretroviral treatment and what type of drugs are used. All participants underwent a blood draw on starting treatment, one after four weeks and after six months. The blood collected will allow researchers to study the levels of circulating stem cells, through which the effect of treatment on the endothelial wall is evaluated.
This study is a clear example of the model of collaboration between basic researchers (studying the properties and functions of the endothelium) and clinical (proposing the involvement of patients in the study and following them up).